Hutch News

Hutch News

Stories tagged 'Philip D Greenberg'

Dr. Phil Greenberg named 2018 Leader in Health Care

Seattle Business Magazine honors cancer immunotherapy pioneer for his work on T-cell therapy

March 2, 2018 | By Susan Keown / Fred Hutch News Service

Seattle Business Magazine honors Fred Hutch cancer immunotherapy pioneer Dr. Phil Greenberg with 2018 Leaders in Health Care Gold Award for Achievement in Medical Research.

View story >

Science to watch in 2018: From immunotherapy to gene therapy, big data to new tech

Fred Hutch experts lend their predictions for the coming year’s advances

Jan. 12, 2018 | By Rachel Tompa / Fred Hutch News Service

We asked Fred Hutch researchers for their predictions on scientific advances to watch in the coming year. Look for their tips on what's next in cancer immunotherapy, precision oncology, gene editing, infectious disease research, cancer prevention and more.

View story >

The latest in gynecological cancer research from the Pacific Northwest

Inaugural Northwest Gynecological Cancer Symposium brings together scientists studying ovarian, cervical and endometrial cancers

Dec. 6, 2017 | By Rachel Tompa / Fred Hutch News Service

Monday, cancer researchers from around the Pacific Northwest gathered at Fred Hutchinson Cancer Research Center to discuss their latest efforts to better prevent, detect and treat cancers of the female reproductive tract in the inaugural Northwest Gynecological Cancer Symposium.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Nov. 30, 2017

The Parker Institute for Cancer Immunotherapy announced that Dr. Phil Greenberg, head of the Program in Immunology at the Hutch, has joined its team of more than 300 scientists from the academic, nonprofit, biotech and pharma sectors.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >

Dr. Carl June weaves together HIV and cancer research to advance cures for both

CAR T-cell pioneer and one-time bone marrow transplant fellow will give keynote at HIV cure conference

Aug. 17, 2017 | By Mary Engel / Fred Hutch News Service

Being in two camps — HIV and cancer research — at one time "made a huge, huge impact on me," says immunotherapy researcher Dr. Carl June.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.